Among existing studies, only one trial (NCT0609766) prospectively enriches for CHIP in CAD (DNMT3A/TET2, VAF ≥ 2%) and evaluates oral NLRP3 inhibition and IL-1 family blockade, yielding short-term biomarker readouts (IL-6, IL-18, hsCRP) rather than hard clinical endpoints. Here, DNMT3A is linked to coronary artery disorder.